You are here

Protalix BioTherapeutics to Release Third Quarter 2019 Financial Results and Business Update on November 7, 2019

CARMIEL, Israel, Oct. 29, 2019 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today announced that it will release its financial results for the third quarter 2019 and business update on Thursday, November 7th, 2019. The Company's management will host a conference call to discuss its financial results and provide a general business update at 8:30 a.m. Eastern Standard Time (EST).

Conference Call Details
Thursday, November 7th at 8:30 a.m. Eastern Standard Time
Domestic (USA):        888-224-1005
International:              323-994-2093
Conference ID:           1931108

The conference call will also be broadcast live and available for replay for two weeks on the Company's website,, in the Events Calendar of the Investors section. Please access the Company's website at least 15 minutes ahead of the conference to register, download and install any necessary audio software.

About Protalix BioTherapeutics, Inc.

Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx®. Protalix was the first company to gain FDA approval of a protein produced through plant cell-based in suspension expression system. Protalix's unique expression system represents a new method for developing recombinant proteins in an industrial-scale manner. Our pipeline consists of proprietary, potentially clinically superior versions of recombinant therapeutic proteins that target established pharmaceutical markets.

Protalix's first product manufactured by ProCellEx, taliglucerase alfa, was approved for marketing by the U.S. Food and Drug Administration (FDA) in May 2012 and, subsequently, by the regulatory authorities of other countries. Protalix has licensed to Pfizer Inc. the worldwide development and commercialization rights for taliglucerase alfa, excluding Brazil, where Protalix retains full rights.

Protalix's development pipeline includes the following product candidates: pegunigalsidase alfa, a modified version of the recombinant human alpha-GAL-A protein for the treatment of Fabry disease, in phase III clinical trials (BALANCE, BRIDGE and BRIGHT studies); and OPRX‑106, an orally delivered anti-inflammatory treatment, and alidornase alfa, both in phase II clinical trials. Protalix has partnered with Chiesi Farmaceutici S.p.A., both in the United States and outside the United States, for the development and commercialization of pegunigalsidase alfa.

Investor Contact
Chuck Padala, Managing Director
LifeSci Advisors
+1 646-627-8390

Media Contact
Doug Russell
+1 617-953-0120

Cision View original content to download multimedia:

SOURCE Protalix BioTherapeutics, Inc.